7Baggers

Evolent Health, Inc
(NYSE:EVH) 

EVH stock logo

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietar...

Founded: 2011
Full Time Employees: 3,400
Sector: Healthcare
Industry: Health Information Services
Technology
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 
                                               
      revenue
    		468,719,000 479,533,000 444,328,000 483,649,000 646,542,000 621,401,000 647,145,000 639,653,000 556,055,000 511,015,000 469,136,000 427,690,000 382,432,000 352,585,000 319,939,000 297,057,000                            
      yoy
    		-27.50% -22.83% -31.34% -24.39% 16.27% 21.60% 37.94% 49.56% 45.40% 44.93% 46.63% 43.98%                                
      qoq
    		-2.26% 7.92% -8.13% -25.19% 4.05% -3.98% 1.17% 15.03% 8.81% 8.93% 9.69% 11.83% 8.47% 10.20% 7.70%                             
      expenses
    		                                           
      cost of revenue
    		371,466,000 379,759,000 343,943,000 381,178,000 570,831,000 540,708,000 540,302,000 535,547,000 454,428,000 386,585,000 351,938,000 310,475,000 299,368,000 266,617,000 249,705,000 219,739,000 164,480,000 163,126,000 172,113,000 157,832,000 176,743,000 183,165,000 165,812,000 175,653,000                    
      selling, general and administrative expenses
    		72,656,000 77,592,000 75,209,000 78,409,000 47,701,000 67,060,000 69,185,000 79,104,000 81,428,000 96,567,000 90,389,000 89,726,000 82,861,000 68,521,000 58,955,000 58,932,000 66,917,000 51,292,000 42,699,000 58,591,000 61,633,000 55,758,000 50,511,000 54,698,000  58,808,000 66,932,000 74,838,000 175,852,000 59,566,000 57,403,000 55,526,000  45,834,000 51,090,000 53,550,000  38,398,000 32,756,000 32,095,000  29,834,000 13,082,000 
      depreciation and amortization expenses
    		45,037,000 23,615,000 23,141,000 24,058,000 29,296,000 29,701,000 29,870,000 29,503,000 29,602,000 32,404,000 32,134,000 29,275,000 19,781,000 17,196,000 15,112,000 15,106,000 15,075,000 14,859,000 14,916,000 15,187,000 14,865,000 14,694,000 15,778,000 16,138,000  15,408,000 15,292,000 14,266,000  10,352,000 10,034,000 9,496,000  7,717,000 6,904,000 6,615,000  3,746,000 3,612,000 3,371,000  3,056,000 984,000 
      loss on lease termination
    		 -1,230,000  1,906,000                                        
      change in fair value of contingent consideration
    		4,658,000 -1,089,000 3,206,000 -280,000 -4,200,000 200,000  8,908,000 5,937,000 11,300,000 -7,822,000 8,569,000 -17,700,000 -12,700,000 800,000 6,078,000            100,000                
      total operating expenses
    		352,354,250 478,647,000 445,499,000 485,271,000 665,138,000 637,669,000 639,357,000 653,062,000 577,405,000 528,953,000 490,704,000 438,045,000 384,310,000 339,634,000 324,572,000 299,855,000 260,572,000 229,052,000 229,728,000 231,016,000 271,870,000 282,301,000 466,101,000 272,785,000  240,281,000 217,192,000 244,402,000  160,977,000 153,264,000 153,846,000  121,932,000 126,188,000 127,693,000  76,049,000 69,147,000 224,628,000  57,652,000 21,953,000 
      operating income
    		-408,231,000 886,000 -1,171,000 -1,622,000 -18,596,000 -16,268,000 7,788,000 -13,409,000 -21,350,000 -17,938,000 -21,568,000 -10,355,000 -1,878,000 12,951,000 -4,633,000 -2,798,000 -12,214,000 -6,581,000 -7,671,000 -15,945,000 53,000 -17,708,000 -227,469,000 -25,500,000  -20,138,000 -25,233,000 -46,646,000  -11,030,000 -8,966,000 -14,132,000  -14,020,000 -19,117,000 -21,455,000  -15,839,000 -12,629,000 -175,179,000  -17,246,000 -11,539,000 
      yoy
    		2095.26% -105.45% -115.04% -87.90% -12.90% -9.31% -136.11% 29.49% 1036.85% -238.51% 365.53% 270.09% -84.62% -296.79% -39.60% -82.45% -23145.28% -62.84% -96.63% -37.47%  -12.07% 801.47% -45.33%  82.57% 181.43% 230.07%  -21.33% -53.10% -34.13%  -11.48% 51.37% -87.75%  -8.16% 9.45%     
      qoq
    		-46175.73% -175.66% -27.81% -91.28% 14.31% -308.89% -158.08% -37.19% 19.02% -16.83% 108.29% 451.38% -114.50% -379.54% 65.58% -77.09% 85.59% -14.21% -51.89% -30184.91% -100.30% -92.22% 792.04%   -20.19% -45.91%   23.02% -36.56%   -26.66% -10.90%   25.42% -92.79%   49.46%  
      operating margin %
    		-87.10% 0.18% -0.26% -0.34% -2.88% -2.62% 1.20% -2.10% -3.84% -3.51% -4.60% -2.42% -0.49% 3.67% -1.45% -0.94% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% 
      interest income
    		868,000 964,000 1,084,000 1,274,000 830,000 794,000 1,370,000 2,550,000 2,521,000 1,071,000 604,000 1,060,000 604,000 425,000 223,000 117,000 96,000 120,000 68,000 123,000 115,000 1,288,000 842,000 919,000  1,124,000 842,000 1,060,000  968,000 878,000 1,072,000  411,000 218,000 185,000  255,000 272,000 279,000  54,000 13,000 
      interest expense
    		-19,010,000 -16,475,000 -11,601,000 -10,385,000 -6,720,000 -6,010,000 -5,995,000 -5,997,000 -12,238,000 -14,614,000 -14,458,000 -12,895,000 -6,429,000 -4,754,000 -2,148,000 -2,241,000 -6,447,000 -6,367,000 -6,274,000 -6,337,000 -8,340,000 -7,419,000 -6,293,000 -6,285,000  -3,630,000 -3,620,000 -3,562,000  -853,000 -855,000 -853,000  -880,000 -947,000 -954,000        
      gain from equity method investees
    		31,000 156,000 197,000 -19,000 182,000 -2,229,000 -1,700,000 306,000 28,000 684,000 155,000 423,000 629,000 1,392,000 1,952,000 596,000 454,000 63,000 4,879,000 7,783,000 -975,000 -13,717,000 25,143,000                     
      gain on extinguishment of short-term debt
    		107,750 431,000                                          
      loss on option exercise
    		  -196,000 -52,348,000                                        
      extinguishment of series a preferred stock and other refinancing fees
    		 -6,000,000                                          
      change in tax receivables agreement liability
    		       -173,000 4,202,000                                   
      other expense
    		252,000 80,000 -35,000  -35,000 -43,000              -14,000                        
      income before income taxes
    		-430,808,000 -19,958,000 -20,722,000 -63,148,000 -23,923,000 -23,756,000 1,358,000 -16,715,000 -48,067,000 -30,874,000 -35,293,000 -88,171,000                                
      provision for income taxes
    		387,750 906,000 -825,000 1,470,000   -238,000 565,000   -970,000 -68,189,000 1,122,000 -45,516,000 -184,000 1,202,000 -453,000 234,000 91,000 611,000                   -371,000     
      loss before preferred dividends and accretion of series a preferred stock including excise tax
    		-429,131,000 -20,864,000                                          
      dividends and accretion of series a preferred stock including excise tax
    		 -6,066,000                                          
      net loss attributable to common shareholders of evolent health, inc.
    		-429,131,000 -26,930,000 -51,090,000 -72,250,000 -30,615,000 -31,231,000 -6,383,000 -25,225,000   -41,411,000 -26,258,000   -4,588,000 -5,350,000 -5,647,000 -13,040,000 -9,107,000 -9,807,000                        
      loss per common share
    		                                           
      basic and diluted
    		-3,760 -240 -440 -630 -260 -270 -60 -220    -240         -70 -440 -2,380 -930                    
      weighted-average common shares outstanding
    		                                           
      basic and diluted
    		114,208,000 114,066,000 115,882,000 115,315,000 114,682,000 114,862,000 114,688,000 114,141,000 111,251  111,278,000 107,783,000 93,699  90,071 89,509 86,067 85,800 85,448 84,670 84,928,000 85,172,000 85,349,000 84,793,000 82,364,000 83,819,000 82,289,000 79,335,000 77,338,000               
      comprehensive loss
    		                                           
      other comprehensive loss, net of taxes, related to:
    		                                           
      foreign currency translation adjustment
    		-248,000 -669,000 22,000 24,000 -386,000 -12,000 -47,000 -51,000 8 -151 8,000 56,000 -134 -262 -288 -132 1 4 -58 -31 42,000 71,000 -4,000 -153,000  -68,000 11,000 24,000  -116,000 -148,000             
      total comprehensive loss attributable to common shareholders of evolent health, inc.
    		-429,379,000 -27,599,000 -51,068,000 -72,226,000 -31,001,000 -31,243,000 -6,430,000 -25,276,000   -41,403,000 -26,202,000   -4,876 -5,482 -5,646 -13,036 -9,165 -9,838 -14,583,000 -37,277,000 -203,525,000 -78,905,000                    
      extinguishment of series a preferred stock
    		  -9,000,000                                         
      income before preferred dividends and accretion of series a preferred stock
    		  -19,897,000    1,596,000  -19,907,250 -25,324,000                                  
      dividends and accretion of series a preferred stock
    		  -31,193,000 -7,632,000 -7,813,000 -8,094,000 -7,979,000 -7,945,000 -7,984,000 -7,872,000 -7,088,000 -6,276,000                                
      other income
    		   -48,000   -105,000 8,000 -220,000 -77,000 -26,000 -220,000 -73,000 -345,000 297,000 178,000 -18,250 -41,000 -18,000  -289,000 -111,000 352,000 -71,000  -84,000 -587,000 427,000  -124,000 78,000 -18,000  15,000 3,000 2,000  1,000 1,000     
      loss before preferred dividends and accretion of series a preferred stock
    		   -64,618,000 -22,802,000 -23,137,000  -17,280,000   -34,323,000 -19,982,000                                
      loss on disposal of non-strategic assets
    		                                           
      right-of-use assets impairment
    		          24,065,000                                 
      benefit from income taxes
    		    -1,121,000 -619,000   -18,677,250 -5,550,000                                  
      loss on disposal of assets
    		        524,250 2,097,000              6,447,000                    
      loss on repayment on long-term debt
    		                                           
      income from continuing operations
    		        -19,907,250 -25,324,000   -1,838,000 2,123,000                              
      loss from discontinued operations, net of tax
    		                                           
      net income attributable to common shareholders of evolent health, inc.
    		        -25,216,250 -33,196,000   -1,953,750 2,123,000       -79,905,250 -37,348,000 -203,521,000 -78,752,000                    
      income per common share
    		                                           
      basic:
    		                                           
      continuing operations
    		        -370 -300 -370  -120 20 -50 -60 40 -150 -110 -130                        
      discontinued operations
    		            -2.5    -110   10                        
      basic income per share attributable to common shareholders of evolent health, inc.
    		        -0.228 -0.3   -0.023 0.02                              
      diluted:
    		                                           
      diluted income per share attributable to common shareholders of evolent health, inc.
    		        -0.228 -0.3   -0.023 0.02                              
      weighted-average common shares outstanding
    		                                           
      basic
    		         112,282    95,286                77,999,000 77,209,000 75,375,000 64,351,000 70,328,000 59,478,000 52,599,000 45,031,000 43,110,000 42,594,000 42,185,000 25,129,000 41,468,000 13,976,000 
      diluted
    		         112,282    99,308                77,999,000 77,209,000 75,375,000 64,351,000 70,328,000 59,478,000 52,599,000 45,031,000 43,110,000 42,594,000 42,185,000 46,136,000 41,468,000 36,643,000 
      comprehensive income
    		                                           
      other comprehensive income, net of taxes, related to:
    		                                           
      total comprehensive income attributable to common shareholders of evolent health, inc.
    		        -25,238 -33,347   -2,124.25 1,861                              
      change in tax receivable agreement liability
    		           -66,184,000 -3,080,000 -42,870,000                              
      loss from continuing operations
    		          -34,323,000    -4,125,000 -5,350,000 3,053,000 -13,040,000 -9,107,000 -11,190,000                        
      loss per common share
    		                                           
      basic and diluted:
    		                                           
      discontinued operations
    		            -2.5    -110   10                        
      basic and diluted
    		          -370                                 
      net income
    		           -26,258,000 -11,349 2,123 -4,588 -5,350 -5,647,000 -13,040,000 -9,107,000 -9,807,000 -13,803,000 -38,170,000 -203,521,000 -78,752,000  -25,738,000 -31,900,000 -48,649,000  -12,555,000 -10,031,000 -14,065,000  -13,129,000 -19,698,000 -23,149,000  -15,775,000 -11,999,000 -173,912,000  -17,088,000 356,488,000 
      yoy
    		           490703.74% -99.80% -100.02% -99.95% -99.95% -59.09% -65.84% -95.53% -87.55%  48.30% 538.00% 61.88%  105.00% 218.01% 245.89%  -4.37% -49.08% -39.24%  -16.77% 64.16% -86.69%  -7.68% -103.37%     
      qoq
    		           231268.40% -634.57% -146.27% -14.24% -99.91% -56.69% 43.19% -7.14% -28.95% -63.84% -81.25% 158.43%   -19.32% -34.43%   25.16% -28.68%   -33.35% -14.91%   31.47% -93.10%   -104.79%  
      net income margin %
    		0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% -6.14% -0.00% 0.00% -0.00% -0.00% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% Infinity% 
      gain on transfer of membership
    		                22,969,000   22,969,000                        
      loss on extinguishment/repayment of debt
    		             -10,192,000                              
      loss from continuing operations before income taxes
    		            -10,227,000 -43,393,000 -4,309,000 -4,148,000 2,600,000 -12,806,000 -9,016,000 -10,579,000                        
      income from discontinued operations, net of tax
    		            -115,750  -463,000  -8,700,000                           
      loss on repayment of debt
    		                -2,185,000   -19,158,000                        
      basic and diluted loss per share attributable to common shareholders of evolent health, inc.
    		              -0.05 -0.06 -0.07 -0.15 -0.11 -0.12                        
      transformation services
    		                6,220,000 2,075,000 2,564,000 345,000 1,190,000 4,807,000 755,000 5,238,000  5,184,000 1,944,000 3,353,000 23,686,000 9,230,000 8,215,000 6,505,000            
      platform and operations services
    		                242,138,000 220,396,000 219,493,000 214,726,000 240,492,000 230,299,000 212,375,000 209,900,000  171,438,000 144,522,000 147,292,000 382,096,000 118,094,000 113,346,000 109,818,000            
      total revenue
    		                248,358,000 222,471,000 222,057,000 215,071,000 271,923,000 264,593,000 238,632,000 247,285,000  220,143,000 191,959,000 197,756,000  149,947,000 144,298,000 139,714,000  107,912,000 107,071,000 106,238,000  60,210,000 56,518,000 49,449,000  40,406,000 10,414,000 
      loss on extinguishment of debt
    		                    -9,578,000 4,789,000                      
      goodwill impairment
    		                      215,100,000                 160,600,000    
      change in fair value of contingent consideration and indemnification asset
    		                14,100,000 -225,000  -594,000 4,352,000 2,570,000 756,000 -3,818,000  -500,000 100,000   100,000 -1,604,000             
      impairment of equity method investments
    		                       -47,133,000                    
      net loss attributable to non-controlling interests
    		                                           
      total comprehensive loss
    		                -5,646 -13,036 -9,165 -9,838 -13,761,000 -38,099,000 -203,525,000 -78,905,000                    
      total comprehensive loss attributable to non-controlling interests
    		                    -205,500 -822,000                      
      gain from discontinued operations, net of tax
    		                   1,383,000                        
      premiums
    		                    30,241,000 29,487,000 25,502,000 32,147,000  43,521,000 45,493,000 47,111,000  22,623,000 22,737,000 23,391,000            
      claims expenses
    		                    24,815,000 21,325,000 18,144,000 23,667,000  34,802,000 36,085,000 37,757,000  16,992,000 18,428,000 16,749,000            
      (gain) loss on disposal of assets
    		                    1,611,750      -9,600,000                 
      income before income taxes and non-controlling interests
    		                    -80,893,500 -37,667,000 -207,425,000 -78,482,000  -26,587,000 -30,502,000 -49,145,000 -41,731,000 -12,420,000 -10,140,000 -14,062,000  -14,843,000 -20,398,000 -22,744,000  -16,031,000 -12,370,000 -174,900,000  -17,192,000 385,761,000 
      benefit for income taxes
    		                    -782,750 503,000 -3,904,000 270,000  -849,000 1,398,000 -496,000  135,000 -109,000 3,000  -1,714,000 -700,000 405,000  -256,000  -988,000  -104,000 29,273,000 
      net income attributable to non-controlling interests
    		                    -205,500 -822,000    -217,000 -285,000 -1,910,000  -126,000 -115,000 -439,000  -541,000 -2,793,000 -5,137,000  -4,567,000 -3,612,000 -51,100,000  -5,108,000 -3,424,000 
      income from equity method investees
    		                       -412,000  -3,859,000 -1,904,000 -424,000  -1,381,000              
      cost of revenue (exclusive of depreciation and amortization
    		                                           
      expenses presented separately below)
    		                         131,763,000 108,383,000 117,441,000  73,967,000 69,003,000 71,975,000  68,281,000 67,994,000 67,528,000  33,905,000 32,779,000     
      net income attributable to evolent health, inc.
    		                         -25,521,000 -31,615,000 -46,739,000  -12,429,000 -9,916,000 -13,626,000  -12,588,000 -16,905,000 -18,012,000  -11,208,000 -8,387,000 -122,812,000  -11,980,000 359,912,000 
      earnings available for common shareholders
    		                                           
      basic and diluted
    		                         -25,521,000 -31,615,000 -46,739,000                
      earnings per common share
    		                                           
      basic and diluted
    		                         -300 -380 -590                
      total comprehensive income
    		                         -25,806,000 -31,889,000 -48,625,000  -12,671,000 -10,179,000 -14,065,000            
      total comprehensive income attributable to non-controlling interests
    		                         -217,000 -285,000 -1,910,000  -126,000 -115,000 -439,000            
      total comprehensive income attributable to evolent health, inc.
    		                         -25,589,000 -31,604,000 -46,715,000  -12,545,000 -10,064,000 -13,626,000            
      earnings available for common shareholders
    		                                           
      basic
    		                             -12,429,000 -9,916,000 -13,626,000  -12,588,000 -16,905,000 -18,012,000  -11,208,000 -8,387,000 -122,812,000  -11,980,000 359,018,000 
      diluted
    		                             -12,429,000 -9,916,000 -13,626,000  -12,588,000 -16,905,000 -18,012,000  -11,208,000 -8,387,000 -122,812,000  -11,980,000 356,488,000 
      earnings per common share
    		                                           
      basic
    		                             -160 -130 -180  -180 -280 -340  -260 -200 -2,910  -290 25,690 
      diluted
    		                             -160 -130 -180  -180 -280 -340  -260 -200 -2,910  -290 9,730 
      income from equity affiliates
    		                              -1,275,000             
      loss on change in fair value of contingent consideration
    		                               100,000  100,000 200,000         
      income from affiliates
    		                               -131,000  -369,000 -555,000 -522,000  -448,000 -14,000     
      transformation
    		                                 8,204,000 5,361,000 10,235,000  7,757,000 10,388,000 8,114,000  6,783,000 2,703,000 
      platform and operations
    		                                 99,708,000 101,710,000 96,003,000  52,453,000 46,130,000 41,335,000  33,623,000 7,711,000 
      gain on consolidation
    		                                          414,133,000 
      presented separately below)
    		                            18,491,750           28,562,000    
      income from affiliate
    		                                          -16,846,000 
      earnings available to common shareholders
    		                                           
      basic
    		                             -12,429,000 -9,916,000 -13,626,000  -12,588,000 -16,905,000 -18,012,000  -11,208,000 -8,387,000 -122,812,000  -11,980,000 359,018,000 
      diluted
    		                             -12,429,000 -9,916,000 -13,626,000  -12,588,000 -16,905,000 -18,012,000  -11,208,000 -8,387,000 -122,812,000  -11,980,000 356,488,000 
      presented below)
    		                                         24,762,000 7,887,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 
                                                 
        assets
      		                                           
        current assets:
      		                                           
        cash and cash equivalents
      		151,856,000 116,650,000 150,995,000 246,547,000 104,203,000 96,583,000 101,250,000 165,147,000 192,825,000 184,536,000 142,530,000 157,519,000 188,200,000 156,756,000 193,070,000 210,158,000 266,280,000 252,496,000 207,273,000 236,032,000 340,490,000 370,514,000 98,272,000 67,944,000 101,008,000 96,734,000 92,821,000 170,817,000 228,320,000 221,837,000 197,983,000 200,316,000 238,433,000 287,143,000 99,975,000 104,295,000 134,563,000 109,777,000 105,138,000 111,292,000 145,726,000 208,157,000 219,367,000 
        restricted cash
      		26,134,000 23,689,000 24,368,000 16,239,000                                  4,990,000 2,205,000 6,747,000 4,703,000 1,322,000 4,397,000 
        accounts receivable
      		309,861,000 386,564,000 358,756,000 430,496,000 414,681,000 407,902,000 373,725,000 427,739,000 446,749,000 394,232,000 345,276,000 262,764,000 254,684,000 187,633,000 118,525,000 179,270,000 130,604,000 175,226,000 242,505,000 185,103,000 125,986,000 95,317,000 95,839,000 107,506,000 75,667,000 74,874,000 71,379,000 65,626,000 80,208,000 60,054,000 70,846,000 66,138,000 48,947,000 43,972,000 45,804,000 44,638,000 40,635,000 21,986,000 30,337,000 25,216,000 20,381,000 30,541,000 24,039,000 
        prepaid expenses and other current assets
      		18,521,000 22,228,000 28,138,000 34,652,000 28,938,000 23,183,000 25,943,000 24,766,000 30,331,000 36,822,000 41,416,000 33,757,000 20,678,000 24,328,000 37,173,000 34,313,000 51,391,000 33,965,000 38,032,000 33,696,000 61,034,000 55,381,000 30,473,000 25,449,000 28,488,000 29,749,000 32,810,000 30,495,000 22,618,000 14,667,000 15,757,000 17,369,000 8,404,000 16,144,000 12,556,000 11,667,000 11,011,000 4,983,000 5,300,000 4,215,000 4,208,000 3,520,000 3,179,000 
        total current assets
      		506,372,000 570,094,000 562,257,000 727,934,000 607,117,000 544,011,000 520,971,000 669,246,000 683,673,000 638,798,000 576,699,000 475,972,000 478,054,000 393,774,000 423,145,000 463,388,000 523,960,000 478,196,000 505,552,000 508,310,000 546,134,000 548,545,000 274,658,000 258,473,000 228,801,000 308,012,000 240,864,000 321,186,000 487,966,000 348,591,000 353,254,000 337,279,000 378,182,000 352,329,000 192,620,000 217,538,000 264,966,000 191,429,000 170,557,000 167,566,000 184,463,000 246,221,000 251,640,000 
        investments and equity method investees
      		8,966,000 8,936,000 8,978,000 8,569,000 8,588,000 8,405,000 8,371,000 8,197,000                                    
        property and equipment
      		80,785,000 80,086,000 77,273,000 74,440,000 73,151,000 73,941,000 75,297,000 76,044,000 78,194,000 79,902,000 83,524,000 88,606,000 87,874,000 94,645,000 92,627,000 82,877,000 81,365,000 81,574,000 82,996,000 84,439,000 86,240,000 88,072,000 88,555,000 85,808,000 85,155,000 83,164,000 80,217,000 77,379,000 73,628,000 68,692,000 64,630,000 60,430,000 50,922,000 46,930,000 40,194,000 35,459,000 31,179,000 21,123,000 18,468,000 15,537,000 12,796,000 10,755,000 8,463,000 
        right-of-use assets - operating
      		4,373,000 4,837,000 5,342,000 5,726,000 6,134,000 9,244,000 9,905,000 10,790,000 11,983,000 17,406,000 27,472,000 44,408,000 49,027,000 50,696,000 50,873,000 48,485,000 50,203,000 50,118,000 51,904,000 53,686,000 57,799,000 60,240,000 66,113,000 63,038,000 72,173,000 75,768,000 76,712,000 63,855,000                
        prepaid expenses and other noncurrent assets
      		3,078,000 2,938,000 4,081,000 3,188,000 3,569,000 3,914,000 2,672,000 2,304,000 4,028,000 3,264,000 3,163,000 3,543,000 2,378,000 3,064,000 6,655,000 7,211,000 6,790,000 6,606,000 6,311,000      6,253,000 7,647,000 10,947,000 11,264,000  15,181,000              
        contract cost assets
      		13,537,000 11,160,000 12,504,000 13,334,000 13,378,000 13,203,000 13,419,000 12,471,000 12,120,000 13,413,000 14,648,000 16,497,000 17,461,000 24,588,000 22,721,000 22,041,000 32,624,000 25,198,000 22,367,000 25,322,000 26,687,000 28,491,000 31,713,000 34,193,000 36,482,000 29,998,000 24,485,000 22,463,000 19,147,000 14,252,000 10,890,000 9,982,000            
        intangible assets
      		584,937,000 623,693,000 651,169,000 667,881,000 680,156,000 696,779,000 711,290,000 731,345,000 752,009,000 777,668,000 801,923,000 825,857,000 442,784,000 451,398,000 264,846,000 272,213,000 279,784,000 245,069,000 252,045,000 259,420,000 268,072,000 275,492,000 282,913,000 291,627,000 308,459,000 317,200,000 326,586,000 336,231,000 335,036,000 230,806,000 236,819,000 242,863,000 241,261,000 249,492,000 254,460,000 254,166,000 258,923,000 162,789,000 165,442,000 168,072,000 163,152,000 165,661,000 168,170,000 
        goodwill
      		694,482,000 1,075,376,000 1,137,321,000 1,137,320,000 1,137,320,000 1,137,342,000 1,116,538,000 1,116,539,000 1,116,542,000 1,117,543,000 1,117,556,000 1,117,945,000 722,774,000 722,790,000 426,228,000 426,274,000 426,297,000 349,010,000 349,009,000 349,022,000 354,734,000 354,722,000 354,695,000 569,797,000 572,064,000 771,887,000 772,164,000 770,334,000 768,124,000 635,088,000 635,282,000 635,246,000 628,186,000 628,341,000 628,653,000 627,204,000 626,569,000 459,703,000 459,703,000 459,703,000 608,903,000 608,903,000 608,903,000 
        total assets
      		1,899,236,000 2,453,459,000 2,461,532,000 2,653,451,000 2,544,411,000 2,501,764,000 2,475,109,000 2,643,673,000 2,680,308,000 2,669,615,000 2,646,831,000 2,589,459,000 1,817,293,000 1,759,182,000 1,303,912,000 1,339,149,000 1,419,458,000 1,253,525,000 1,293,367,000 1,305,584,000 1,370,185,000 1,391,789,000 1,270,134,000 1,450,754,000 1,498,015,000 1,713,901,000 1,652,256,000 1,629,374,000 1,722,281,000 1,322,676,000 1,321,620,000 1,306,310,000 1,312,697,000 1,299,030,000 1,138,352,000 1,154,446,000 1,199,839,000 851,280,000 852,801,000 856,463,000 1,015,514,000 1,056,181,000 1,039,837,000 
        liabilities, mezzanine equity and shareholders’ equity
      		                                           
        liabilities
      		                                           
        current liabilities:
      		                                           
        accounts payable
      		59,776,000 72,180,000 69,460,000 57,813,000 96,025,000 50,087,000 39,030,000 77,346,000 48,246,000 51,776,000 76,953,000 51,012,000 57,174,000 61,863,000 96,565,000 64,036,000 96,084,000 37,785,000 39,879,000 78,574,000 32,068,000 32,177,000 73,691,000 80,035,000 37,488,000 120,024,000 28,758,000 39,007,000 146,760,000 30,535,000 34,258,000 22,445,000 42,930,000 27,292,000 26,280,000 39,613,000 43,892,000 14,486,000 12,375,000 17,042,000 16,699,000 12,642,000 13,530,000 
        accrued liabilities
      		65,755,000 60,893,000 63,886,000 99,531,000 66,361,000 120,454,000 84,788,000 165,099,000 149,849,000 193,961,000 166,676,000 170,236,000 111,198,000 132,238,000 75,846,000 115,068,000 107,241,000 55,774,000 52,339,000 61,069,000 84,507,000 76,979,000 35,305,000 28,203,000 33,343,000 41,632,000 52,631,000 53,018,000 48,957,000 47,189,000 39,477,000 37,955,000 29,572,000 21,094,000 25,919,000 22,320,000 29,160,000 11,839,000 8,513,000 7,551,000 6,047,000 21,682,000 20,091,000 
        operating lease liability - current
      		15,343,000 17,942,000 24,208,000 35,187,000 26,717,000 6,220,000 6,133,000 12,696,000 9,738,000 12,966,000 6,218,000 4,608,000 7,122,000 7,053,000 6,389,000 6,445,000 7,069,000 6,730,000 7,265,000 7,539,000 7,357,000 7,438,000 7,474,000 5,785,000 6,269,000                   
        accrued compensation and employee benefits
      		50,987,000 55,380,000 38,262,000 35,914,000 33,719,000 31,614,000 31,302,000 29,106,000 56,385,000 50,095,000 38,290,000 27,527,000 52,460,000 37,646,000 29,371,000 19,390,000 51,861,000 34,542,000 25,852,000 19,360,000 48,278,000 28,130,000 20,996,000 16,195,000 34,691,000 27,031,000 26,860,000 15,872,000 25,460,000 28,989,000 23,168,000 16,508,000 35,390,000 30,987,000 21,787,000 16,993,000 38,408,000 21,287,000 16,991,000 9,623,000 21,925,000   
        deferred revenue
      		1,203,000 1,871,000 2,333,000 5,017,000 2,507,000 2,621,000 4,558,000 6,136,000 5,976,000 5,763,000 6,950,000 7,069,000 5,758,000 7,524,000 8,711,000 13,288,000 11,944,000 13,785,000 13,173,000 13,367,000 14,327,000 12,459,000 13,247,000 17,023,000 19,828,000 22,701,000 26,923,000 22,320,000 20,584,000 22,360,000 29,818,000 33,328,000 24,807,000 26,094,000 27,774,000 25,513,000 20,481,000 17,717,000 18,848,000 18,329,000 14,835,000 33,466,000 27,091,000 
        short-term debt
      		 5,118,000 172,119,000 171,793,000 171,467,000     991,000                                  
        reserve for claims and performance - based arrangements
      		192,196,000 211,652,000 187,251,000 333,842,000 318,705,000 312,687,000 317,563,000 368,639,000 404,048,000 299,742,000 245,811,000 197,197,000 199,730,000 135,698,000 125,960,000 164,238,000 171,294,000 191,878,000 238,105,000 207,993,000                        
        total current liabilities
      		385,260,000 429,927,000 557,519,000 739,097,000 715,501,000 523,683,000 483,374,000 659,022,000 674,242,000 615,294,000 540,898,000 457,649,000 433,442,000 382,022,000 342,842,000 382,465,000 445,493,000 367,198,000 403,268,000 414,508,000 401,779,000 365,496,000 245,122,000 236,251,000 192,769,000 259,851,000 172,873,000 163,675,000 269,356,000 139,411,000 136,187,000 116,935,000 132,699,000 105,467,000 101,760,000 104,439,000 131,941,000 65,329,000 56,727,000 52,545,000 59,506,000 89,838,000 60,806,000 
        long-term debt
      		970,537,000 1,054,822,000 648,455,000 647,532,000 490,520,000 599,668,000 598,784,000 597,901,000 597,049,000 599,947,000 633,013,000 632,277,000 412,986,000 412,444,000 283,138,000 282,598,000 215,676,000 211,063,000 206,550,000 202,132,000 263,343,000 285,213,000 299,746,000 296,676,000 293,667,000 227,996,000 225,642,000 223,320,000 221,041,000 122,082,000 121,853,000 121,623,000 121,394,000 121,164,000 120,935,000 120,706,000 120,283,000       
        other long-term liabilities
      		8,012,000 3,784,000 3,787,000 3,269,000 2,984,000 3,247,000 3,431,000 3,568,000 3,637,000 3,978,000 4,273,000 4,473,000 4,744,000 4,260,000 4,619,000 4,999,000 5,531,000 9,474,000 9,784,000 10,269,000 22,209,000 20,207,000 10,101,000 7,664,000 11,732,000 6,553,000 10,423,000 10,490,000 17,090,000 10,885,000 10,666,000 11,368,000 9,861,000 9,982,000 10,024,000 14,091,000 14,655,000 7,997,000 7,972,000 7,927,000 111,000 67,000  
        tax receivables agreement liability
      		108,909,000 108,105,000 108,105,000 108,105,000 108,105,000 108,105,000 108,105,000 108,105,000 107,932,000 112,134,000                                  
        operating lease liabilities - noncurrent
      		3,818,000 4,433,000 8,411,000 15,585,000 24,969,000 29,318,000 30,789,000 32,469,000 38,009,000 39,650,000 56,576,000 54,274,000 56,010,000 57,840,000 58,581,000 56,354,000 57,722,000 57,283,000 58,618,000 60,292,000 62,526,000 64,738,000 66,975,000 60,961,000 68,858,000 70,560,000 70,796,000 57,197,000                
        deferred tax liabilities
      		7,506,000 10,155,000 10,450,000 11,114,000 10,900,000 11,892,000 12,559,000 13,378,000 13,311,000 26,913,000 33,889,000 36,284,000 4,744,000 3,608,000 1,644,000 1,524,000 1,403,000 1,023,000 957,000 1,085,000 728,000 1,390,000 1,326,000 2,130,000 1,942,000 24,593,000 25,766,000 24,566,000 25,438,000 1,725,000 1,533,000 1,470,000 2,437,000 6,638,000 11,184,000 18,470,000 20,846,000 18,097,000 19,958,000 20,329,000 21,318,000 30,224,000 30,327,000 
        total liabilities
      		1,484,042,000 1,611,226,000 1,336,727,000 1,524,702,000 1,352,979,000 1,275,913,000 1,237,042,000 1,414,443,000 1,434,180,000 1,397,916,000 1,380,783,000 1,297,091,000 957,876,000 903,044,000 690,824,000 727,940,000 725,825,000 646,041,000 679,177,000 688,286,000 750,585,000 737,044,000 623,270,000 603,682,000 568,968,000 589,553,000 505,500,000 479,248,000 532,925,000 274,103,000 270,239,000 251,396,000 266,391,000 243,251,000 243,903,000 257,706,000 287,725,000 91,423,000 84,657,000 80,801,000 80,935,000 120,129,000 91,133,000 
        mezzanine equity
      		                                           
        preferred class a common stock - 0.01 par value...
      		  228,800,000 193,228,000 190,173,000 187,166,000 184,206,000 181,294,000 178,427,000 175,606,000 172,829,000 170,625,000                                
        shareholders' equity
      		                                           
        class a common stock - 0.01 par value...
      		1,176,000 1,176,000 1,175,000 1,174,000 1,166,000 1,166,000 1,163,000 1,162,000 1,154,000 1,148,000 1,131,000 1,125,000 1,015,000 1,012,000 916,000 916,000 908,000 874,000 872,000 868,000 859,000 858,000 855,000 855,000 846,000                   
        additional paid-in-capital
      		1,793,398,000 1,791,060,000 1,782,992,000 1,802,634,000 1,803,786,000 1,818,024,000 1,810,054,000 1,805,679,000 1,808,121,000  1,774,784,000 1,768,999,000 1,486,857,000 1,472,098,000 1,231,005,000 1,224,250,000 1,340,989,000 1,249,228,000 1,242,900,000 1,236,847,000 1,229,320,000 1,224,956,000 1,183,605,000 1,180,288,000 1,173,708,000    1,093,174,000  961,472,000 953,322,000 924,153,000 919,962,000 747,385,000 621,187,000 555,250,000 397,603,000 361,895,000 357,047,000 342,063,000 335,269,000 330,833,000 
        accumulated other comprehensive loss
      		-2,624,000 -2,376,000 -1,707,000 -1,729,000 -1,753,000 -1,367,000 -1,355,000 -1,308,000 -1,257,000  -1,114,000 -1,122,000 -1,178,000 -1,044,000 -782,000 -494,000                            
        retained earnings
      		-1,315,327,000 -886,196,000 -865,332,000 -845,435,000 -780,817,000 -758,015,000 -734,878,000 -736,474,000 -719,194,000    -606,154,000 -594,805,000 -596,928,000 -592,340,000 -626,779,000 -621,132,000 -608,092,000 -598,985,000 -589,178,000 -574,553,000 -537,205,000 -333,684,000 -251,962,000 -53,866,000 -28,345,000 3,270,000 50,009,000 66,696,000 79,125,000 89,041,000 85,952,000 99,111,000 111,699,000 128,605,000 146,617,000 164,024,000 175,232,000 183,876,000 306,688,000 310,807,000 322,787,000 
        treasury stock
      		-61,429,000 -61,431,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000    -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000 -21,123,000                      
        total shareholders’ equity
      		415,194,000  896,005,000                                         
        total liabilities, mezzanine equity and shareholders’ equity
      		1,899,236,000  2,461,532,000                                         
        assets held for sale - current
      		 20,963,000                                          
        assets held for sale - noncurrent
      		 73,674,000                                          
        liabilities held for sale - current
      		 4,891,000                                          
        commitments and contingencies
      		                                           
        restricted cash and restricted investments
      		    59,295,000 16,343,000 20,053,000 51,594,000 13,768,000 23,208,000 47,477,000 21,932,000 14,492,000 25,057,000 74,377,000 39,647,000 75,685,000 16,509,000 17,742,000 53,479,000 14,437,000 21,985,000 46,894,000 54,409,000 20,080,000 101,475,000 38,619,000 50,920,000 154,718,000 42,328,000 53,660,000 33,364,000 62,398,000 5,070,000 10,258,000 23,254,000 34,416,000       
        total shareholders' equity
      		    1,001,259,000    1,067,701,000    859,417,000 856,138,000 613,088,000 611,209,000 693,633,000 607,484,000 614,190,000 617,298,000 619,600,000 654,745,000 646,864,000 847,072,000 929,047,000 1,124,348,000 1,146,756,000 1,150,126,000 1,189,356,000 1,048,573,000 1,051,381,000 1,054,914,000 1,046,306,000 1,055,779,000 894,449,000 896,740,000        
        total liabilities, mezzanine equity and shareholders' equity
      		    2,544,411,000    2,680,308,000                                   
        investments in equity method investees
      		        4,895,000 4,867,000 4,254,000 4,112,000 4,475,000 5,222,000 3,831,000 3,679,000 5,458,000                           
        tax receivable agreement liability
      		          112,134,000 112,134,000 45,950,000 42,870,000                              
        liabilities and shareholders’ equity
      		                                           
        total liabilities and shareholders' equity
      		            1,817,293,000 1,759,182,000 1,303,912,000 1,339,149,000 1,419,458,000 1,253,525,000 1,293,367,000 1,305,584,000 1,370,185,000 1,391,789,000 1,270,134,000 1,450,754,000 1,498,015,000 1,713,901,000 1,652,256,000 1,629,374,000 1,722,281,000 1,322,676,000 1,321,620,000 1,306,310,000 1,312,697,000 1,299,030,000 1,138,352,000 1,154,446,000  851,280,000 852,801,000 856,463,000    
        current assets of discontinued operations
      		                                           
        non-current assets of discontinued operations
      		                                           
        short-term debt, net of discount
      		                 26,704,000 26,655,000 26,606,000 26,557,000                       
        current liabilities of discontinued operations
      		                                           
        non-current liabilities from discontinued operations
      		                                           
        accumulated other comprehensive income
      		                -362,000 -363,000 -367,000 -309,000 -278,000 -320,000 -391,000 -387,000 -234,000 -215,000 -147,000 -158,000 -182,000 -264,000 -148,000             
        investments in and advances to equity method investees
      		                 5,004,000 9,788,000 4,909,000 6,498,000 7,473,000 100,216,000 75,074,000 122,618,000 55,528,000 59,167,000 6,188,000 6,276,000 5,672,000              
        prepaid expenses and other noncurrent assets, net of allowances
      		                   6,218,000 5,832,000 7,450,000 6,437,000 5,801,000                    
        investments, at amortized cost
      		                    3,858,000 4,677,000 834,000 1,413,000 1,807,000 3,815,000 4,048,000 2,046,000 10,010,000      24,027,000 33,684,000 44,341,000 49,693,000 27,577,000 20,096,000 9,445,000 2,023,000  
        contract assets
      		                    329,000 671,000 2,346,000 1,752,000 1,751,000 1,365,000 1,187,000 1,282,000 2,102,000 3,705,000 3,008,000 4,092,000            
        customer advance for regulatory capital requirements, net of allowances
      		                      39,955,000 39,955,000                    
        reserve for claims and performance-based arrangements
      		                    188,685,000 208,313,000 94,409,000 89,010,000 61,150,000  33,052,000 30,019,000                
        total shareholders' equity attributable to evolent health, inc.
      		                    619,600,000 629,818,000 646,864,000                     
        non-controlling interests
      		                     24,927,000   6,689,000 15,888,000 16,078,000 50,100,000 45,532,000 10,008,000 10,148,000 11,772,000 35,427,000 35,932,000 34,680,000 146,269,000 209,588,000 197,629,000 230,416,000 234,138,000 285,238,000 289,386,000 294,494,000 
        total shareholders' equity (deficit) attributable to evolent health, inc.
      		                       847,072,000 922,358,000 1,108,460,000 1,130,678,000 1,100,026,000 1,143,824,000 1,038,565,000 1,041,233,000 1,043,142,000 1,010,879,000 1,019,847,000 859,769,000 750,471,000 702,526,000 562,228,000 537,728,000 541,524,000 649,341,000 646,666,000 654,210,000 
        customer advance for regulatory capital requirements
      		                        40,000,000 40,000,000 40,000,000                 
        class b common stock - 0.01 par value...
      		                                           
        operating lease liabilities - current
      		                         5,390,000 4,649,000 3,439,000                
        reserves for claims and performance-based arrangements
      		                         43,073,000                  
        83,825,595 and 79,172,118 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively
      		                         838,000                  
        706,273 and 3,190,301 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively
      		                         7,000                  
        additional paid-in capital
      		                         1,161,696,000 1,158,325,000 1,096,089,000  971,341,000              
        83,814,852 and 79,172,118 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively
      		                          838,000                 
        706,273 and 3,190,301 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively
      		                          7,000                 
        79,428,728 and 79,172,118 shares issued and outstanding as of march 31, 2019 and december 31, 2018, respectively
      		                           794,000                
        3,190,301 shares issued and outstanding as of march 31, 2019 and december 31, 2018
      		                           31,000                
        notes receivable
      		                             6,000,000 12,000,000 16,000,000 20,000,000           
        prepaid expenses and other noncurrent assets (amounts related to affiliates: 2018 - 2,500; 2017 - 0
      		                            15,028,000               
        claims reserves
      		                            27,595,000 10,338,000 9,466,000 6,699,000            
        79,172,118 and 74,723,597 shares issued and outstanding as of december 31, 2018 and 2017, respectively
      		                            792,000               
        3,190,301 and 2,653,544 shares issued and outstanding as of december 31, 2018 and 2017, respectively
      		                            31,000               
        shares issued and outstanding as of september 30, 2018, and december 31, 2017, respectively
      		                             784,000              
        investments in and advances to affiliates
      		                              4,246,000 5,521,000 1,531,000 712,000 1,081,000 1,636,000 2,159,000 2,538,000 2,986,000     
        prepaid expenses and other non-current assets
      		                              11,838,000 10,045,000 9,328,000 9,364,000 9,483,000 9,782,000 10,043,000 12,118,000 9,859,000 10,127,000    
        shares issued and outstanding as of june 30, 2018, and december 31, 2017, respectively
      		                              776,000             
        shares issued and outstanding as of march 31, 2018, and december 31, 2017, respectively
      		                               770,000            
        74,723,597 and 52,586,899 shares issued and outstanding as of december 31, 2017 and 2016, respectively
      		                                747,000           
        2,653,544 and 15,346,981 shares issued and outstanding as of december 31, 2017 and 2016, respectively
      		                                27,000           
        shares issued and outstanding as of september 30, 2017, and december 31, 2016, respectively
      		                                 747,000          
        shares issued and outstanding as of june 30, 2017, and december 31, 2016, respectively
      		                                  658,000         
        shares issued and outstanding as of march 31, 2017, and december 31, 2016, respectively
      		                                   570,000        
        52,586,899 and 41,491,498 shares issued and outstanding as of december 31, 2016 and 2015, respectively
      		                                    506,000       
        15,346,981 and 17,524,596 shares issued and outstanding as of december 31, 2016 and 2015, respectively
      		                                    153,000       
        total equity
      		                                    912,114,000 759,857,000 768,144,000 775,662,000 934,579,000 936,052,000 948,704,000 
        total liabilities, redeemable preferred stock and shareholders' equity
      		                                    1,199,839,000    1,015,514,000 1,056,181,000 1,039,837,000 
        shares issued and outstanding as of september 30, 2016, and december 31, 2015, respectively
      		                                     448,000      
        shares issued and outstanding as of june 30, 2016, and december 31, 2015, respectively
      		                                      426,000     
        shares issued and outstanding as of june 30, 2016, and december 31, 2015
      		                                      175,000     
        shares issued and outstanding as of march 31, 2016, and december 31, 2015, respectively
      		                                       426,000    
        shares issued and outstanding as of march 31, 2016, and december 31, 2015
      		                                       175,000    
        equity method investment
      		                                           
        liabilities, redeemable preferred stock and shareholders’ equity
      		                                           
        redeemable preferred stock
      		                                           
        series a redeemable preferred stock - zero and 7,900,000 shares authorized, issued and outstanding as of december 31, 2015 and
      		                                           
        2014, respectively; liquidation value of zero and 25,018 as of december 31, 2015 and 2014, respectively
      		                                           
        series b redeemable preferred stock - zero and 6,467,376 shares authorized, issued and outstanding as of december 31, 2015
      		                                           
        2014, respectively; liquidation value of zero and 27,359 as of december 31, 2015 and 2014, respectively
      		                                           
        series b-1 redeemable preferred stock - zero and 1,953,124 shares authorized as of december 31, 2015 and 2014, respectively;
      		                                           
        zero and 360,420 shares issued and outstanding as of december 31, 2015 and 2014, respectively; liquidation value of zero
      		                                           
        and 1,478 as of december 31, 2015 and 2014, respectively
      		                                           
        total redeemable preferred stock
      		                                           
        series a preferred stock - 0.001 par value...
      		                                           
        zero and 7,400,000 shares issued and outstanding as of december 31, 2015 and 2014, respectively; liquidation value of zero
      		                                           
        and 23,200 as of december 31, 2015 and 2014, respectively
      		                                           
        respectively; 41,491,498 and 4,047,484 shares issued and outstanding as of december 31, 2015 and 2014, respectively
      		                                        415,000   
        17,524,596 and zero shares issued and outstanding as of december 31, 2015 and 2014, respectively
      		                                        175,000   
        deferred tax assets
      		                                         658,000 658,000 
        other non-current assets
      		                                         82,000 151,000 
        investment payable
      		                                         22,048,000  
        series a redeemable preferred stock - zero and 7,900,000 shares authorized, issued and outstanding as of september 30, 2015, and
      		                                           
        december 31, 2014, respectively; liquidation value of zero and 25,018 as of september 30, 2015, and december 31, 2014,
      		                                           
        respectively
      		                                           
        series b redeemable preferred stock - zero and 6,467,376 shares authorized, issued and outstanding as of september 30, 2015, and
      		                                           
        december 31, 2014, respectively; liquidation value of zero and 27,359 as of september 30, 2015, and december 31, 2014,
      		                                           
        series b-1 redeemable preferred stock - zero and 1,953,124 shares authorized as of september 30, 2015, and december 31, 2014,
      		                                           
        respectively; zero and 360,420 shares issued and outstanding as of september 30, 2015, and december 31, 2014, respectively;
      		                                           
        liquidation value of zero and 1,478 as of september 30, 2015, and december 31, 2014, respectively
      		                                           
        2014, respectively; zero and 7,400,000 shares issued and outstanding as of september 30, 2015, and december 31, 2014,
      		                                           
        respectively; liquidation value of zero and 23,200 as of september 30, 2015, and december 31, 2014, respectively
      		                                           
        december 31, 2014, respectively; 41,475,498 and 4,047,484 shares issued and outstanding as of september 30, 2015, and
      		                                           
        december 31, 2014, respectively
      		                                         415,000  
        2014, respectively; 17,524,596 and zero shares issued and outstanding as of september 30, 2015, and december 31, 2014,
      		                                           
        other current liabilities
      		                                          94,000 
        series a redeemable preferred stock - zero and 7,900,000 shares authorized, issued and outstanding as of june 30, 2015, and
      		                                           
        and december 31, 2014, respectively; liquidation value of zero and 25,018 as of june 30, 2015, and december 31, 2014,
      		                                           
        series b redeemable preferred stock - zero and 6,467,376 shares authorized, issued and outstanding as of june 30, 2015, and
      		                                           
        december 31, 2014, respectively; liquidation value of zero and 27,359 as of june 30, 2015, and december 31, 2014, respectively
      		                                           
        series b-1 redeemable preferred stock - zero and 1,953,124 shares authorized as of june 30, 2015, and december 31, 2014,
      		                                           
        respectively; zero and 360,420 shares issued and outstanding as of june 30, 2015, and december 31, 2014, respectively;
      		                                           
        liquidation value of zero and 1,478 as of june 30, 2015, and december 31, 2014, respectively
      		                                           
        respectively; zero and 7,400,000 shares issued and outstanding as of june 30, 2015, and december 31, 2014; liquidation value of
      		                                           
        zero and 23,200 as of june 30, 2015, and december 31, 2014, respectively
      		                                           
        2014, respectively; 41,461,748 and 4,047,484 shares issued and outstanding as of june 30, 2015, and december 31, 2014,
      		                                           
        respectively; 17,524,596 and zero shares issued and outstanding as of june 30, 2015, and december 31, 2014, respectively
      		                                          175,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2016-06-30 
                                 
          cash flows from operating activities
        		                         
          loss before preferred dividends and accretion of series a preferred stock including excise tax
        		-429,131,000                         
          adjustments to reconcile net loss to net cash and restricted cash from operating activities:
        		                         
          change in fair value of contingent consideration
        		4,658,000 -1,089,000 3,206,000 -280,000 -4,200,000 200,000 0 8,908,000 5,937,000 11,300,000 -7,822,000 8,569,000 -17,700,000 -12,700,000 800,000 6,078,000          
          loss on disposal of non-strategic assets
        		                         
          loss from equity method investees
        		-31,000 -156,000 -197,000 19,000 -182,000 2,229,000           -454,000 -63,000 -4,879,000 -7,783,000      
          extinguishment of series a preferred stock and other refinancing fees
        		0                         
          loss on option exercise
        		0 0 196,000 52,348,000                      
          depreciation and amortization expenses
        		45,037,000 23,615,000 23,141,000 24,058,000 29,296,000 29,701,000 29,870,000 29,503,000 29,602,000 32,404,000 32,134,000 29,275,000 19,781,000 17,196,000 15,112,000 15,106,000 14,915,000 14,859,000 14,916,000 15,347,000 14,865,000 14,694,000 15,778,000 16,138,000 6,983,000 
          stock-based compensation expense
        		2,396,000 14,682,000 11,580,000 11,081,000 -6,115,000 14,416,000 12,659,000 18,786,000 10,603,000 10,222,000 8,966,000 10,710,000 14,631,000 6,992,000 7,012,000 5,346,000 4,957,000 4,395,000 3,653,000 3,706,000 4,231,000 3,164,000 3,703,000 3,508,000 9,513,000 
          deferred tax benefit
        		    -1,073,000    -15,058,000    777,000         119,000 -950,000 58,000  
          amortization of contract cost assets
        		1,090,000 3,181,000 1,286,000 1,237,000 1,194,000 1,285,000 1,114,000 1,205,000 2,939,000 2,333,000 3,382,000 2,290,000 8,288,000 1,582,000 1,497,000 11,689,000 3,113,000 1,617,000 5,256,000 3,055,000 5,258,000 5,665,000 4,658,000 5,614,000  
          amortization of deferred financing costs
        		3,042,000 2,359,000 1,249,000 1,154,000 897,000 885,000 883,000 882,000 900,000 997,000 1,004,000 911,000 540,000 683,000 540,000 539,000 4,646,000 4,562,000 4,467,000 4,370,000 4,687,000 4,014,000 3,070,000 3,009,000  
          goodwill impairment
        		                    0 0   160,600,000 
          loss on extinguishment/repayment of debt
        		            0             
          right-of-use asset impairment
        		        0 0                
          loss on lease termination
        		0 -1,230,000 0 1,906,000                      
          change in tax receivables agreement liability
        		    0 0 0 173,000 -4,202,000                 
          right-of-use operating assets
        		464,000 505,000 384,000 408,000 522,000 799,000 747,000 1,193,000 5,496,000 9,982,000 -3,473,000 4,620,000 1,669,000 1,500,000 -2,387,000 1,718,000 2,436,000 1,787,000 1,781,000 2,840,000 2,441,000 5,873,000 -3,075,000 6,695,000  
          other current operating cash inflows (outflows)
        		   2,000 0        449,000 1,471,000 1,049,000 -357,000     935,000 1,585,000 -300,000 524,000  
          changes in assets and liabilities, net of acquisitions:
        		                         
          accounts receivable, net and contract assets
        		66,339,000 -48,561,000 71,740,000 -15,815,000 -6,782,000 -34,177,000 54,012,000 19,009,000 -52,517,000 -49,040,000 -82,969,000 19,832,000 -68,184,000 -47,838,000 59,341,000 -46,299,000 47,099,000 67,188,000 -56,833,000 -63,233,000 -31,352,000 8,281,000 12,703,000 -36,649,000  
          prepaid expenses and other current and non-current assets
        		4,600,000 2,191,000 5,926,000 -7,729,000 -3,241,000 1,816,000 -1,231,000 7,166,000 5,781,000 4,748,000 -7,384,000 -13,758,000 4,082,000 6,044,000 -2,382,000 -6,071,000 5,739,000 3,299,000 -4,476,000 1,037,000      
          contract cost assets
        		-3,467,000 -1,837,000 -456,000 -1,193,000 -1,369,000 -1,068,000 -2,063,000 -1,556,000 -1,644,000 -1,099,000 -1,533,000 -1,326,000 -961,000 -3,448,000 -2,178,000 -1,106,000 -10,540,000 -4,448,000 -2,301,000 -1,690,000 -3,454,000 -2,443,000 -2,177,000 -3,326,000  
          accounts payable
        		-14,862,000 3,312,000 14,925,000 3,264,000 2,988,000 16,590,000 -6,909,000 -8,421,000 5,905,000 104,000 853,000 -13,585,000 7,229,000 6,759,000 -1,249,000 426,000 -914,000 -1,740,000 509,000 9,395,000 3,941,000 -12,084,000 622,000 11,068,000 -2,975,000 
          accrued liabilities
        		7,356,000 1,468,000 13,012,000 -18,879,000 -41,846,000 18,138,000 -11,125,000 10,635,000 -3,884,000 15,593,000 7,159,000 4,785,000 -888,000 -3,077,000 -27,046,000 2,220,000 13,569,000 3,832,000 -8,027,000 -9,698,000 2,537,000 2,193,000 4,749,000 -678,000 2,524,000 
          operating lease liabilities
        		-3,214,000 -9,014,000 -18,153,000 -2,820,000 -2,774,000 -1,521,000 -8,106,000 -2,582,000 -4,941,000 -10,094,000 3,912,000 -4,250,000 -1,760,000 -1,402,000 2,171,000 -1,992,000 -1,933,000 -1,870,000 -1,948,000 -771,000 -2,292,000 -2,273,000 7,703,000 -5,920,000  
          accrued compensation and employee benefits
        		-4,393,000 17,118,000 2,348,000 2,195,000 2,105,000 285,000 2,214,000 -27,279,000 6,755,000 11,836,000 10,758,000 -31,401,000 14,898,000 7,928,000 10,056,000 -32,435,000 16,349,000 8,694,000 6,509,000 -28,014,000 15,793,000 5,468,000 8,025,000 -18,143,000 -4,934,000 
          deferred revenue
        		-668,000 -462,000 -2,684,000 2,510,000 -114,000 -1,937,000 -1,578,000 160,000 -127,000 -1,186,000 -119,000 1,169,000 -1,767,000 -1,508,000 -4,577,000 1,344,000 -3,842,000 613,000 -194,000 2,684,000 1,868,000 -4,411,000 -3,777,000 -2,623,000 4,013,000 
          reserve for claims and performance-based arrangements
        		-19,456,000 24,401,000 -146,591,000 15,137,000 6,018,000 -4,876,000 -51,076,000 -35,409,000 104,306,000 53,931,000 48,614,000 -2,533,000 64,032,000 9,738,000 -38,278,000 -7,056,000 -20,583,000 -45,830,000 30,113,000 32,501,000 -19,629,000 -49,738,000 5,399,000 27,860,000  
          other long-term liabilities
        		4,228,000 -3,000 518,000 285,000 -263,000 -189,000 -136,000 -65,000 0 -282,000 -200,000 -277,000 -523,000 -326,000 -344,000 -514,000 -3,942,000 -310,000 -407,000 1,925,000 3,758,000 3,935,000 380,000 93,000 91,000 
          net cash and restricted cash from operating activities
        		48,800,000 15,812,000 -30,334,000 4,565,000 -26,231,000 18,670,000 21,417,000 4,909,000 89,381,000 60,521,000 654,000 -7,974,000 35,695,000 -3,470,000 13,664,000 -57,442,000 66,656,000 44,501,000 -24,247,000 -48,163,000 -12,851,000 -20,499,000 37,666,000 -20,541,000  
          cash flows from investing activities
        		                         
          cash paid for asset acquisitions and business combinations
        		-1,398,000 2,000 -51,549,000 -4,498,000 -13,778,000 -11,000,000 -4,562,000 -1,385,000 0 0 -1,522,000 -386,724,000 -3,090,000 -235,951,000 -9,000,000 -70,000          
          proceeds from disposal of non-strategic assets
        		                         
          return of equity method investments
        		0 198,000   0 0   0 71,000 13,000 786,000 1,377,000 0 1,800,000 2,375,000 0 4,846,000 0 9,372,000      
          purchases of investments and contributions to equity method investees
        		0 0   -1,000 -2,440,000                    
          investments in internal-use software and purchases of property and equipment
        		-7,761,000 -8,962,000 -8,770,000 -8,595,000 -6,151,000 -6,289,000 -7,106,000 -5,347,000 -6,052,000 -6,793,000 -6,845,000 -9,055,000 -10,743,000 -9,874,000 -9,236,000 -8,508,000 -7,244,000 -6,227,000 -5,571,000 -5,941,000 -5,859,000 -6,159,000 -10,055,000 -7,400,000  
          net cash and restricted cash from investing activities
        		82,153,000 -8,762,000 -60,531,000 -13,093,000 -19,930,000 -19,729,000 -13,541,000 -9,732,000 -6,052,000 -6,145,000 -8,354,000 -394,993,000 -4,456,000 -254,989,000 -16,436,000 16,766,000 -54,368,000 -1,798,000 -5,571,000 45,951,000 -2,225,000 281,679,000 -7,575,000 -10,807,000  
          cash flows from financing activities
        		                         
          changes in working capital balances related to claims processing
        		2,444,000 -578,000 -3,278,000 -41,476,000 42,953,000 -5,525,000 -31,411,000 37,520,000                  
          payment of contingent consideration
        		0 -750,000   0 0 -66,600,000 -3,755,000                  
          proceeds from stock option exercises
        		    -1,000 2,343,000 61,000 1,058,000 3,336,000 4,529,000 3,073,000 1,581,000 1,172,000 2,971,000 0 309,000 1,723,000 2,190,000 2,858,000 6,518,000   442,000 84,000 114,000 
          proceeds from issuance of preferred stock, net of offering costs
        		        0 0 0 168,000,000              
          proceeds from issuance of long-term debt, net of offering costs
        		18,307,000 168,740,000 0 221,000,000 59,105,000 0 0 -529,000 391,431,000 0 -267,000 256,330,000              
          repayment of debt
        		                         
          repurchase of common stock
        		0                         
          payment of preferred dividends
        		0 -1,929,000 -4,621,000 -4,577,000 -4,806,000 -5,134,000 -5,067,000 -5,078,000 -5,162,000 -5,096,000 -4,884,000 -3,651,000              
          taxes withheld and paid for vesting of equity awards
        		-58,000 -547,000 -28,000 -4,593,000 -309,000 -692,000 -364,000 -14,334,000 -944,000 -1,603,000 -138,000 -12,607,000 -899,000 -948,000 -257,000 -16,214,000          
          net cash and restricted cash from financing activities
        		-93,036,000 -41,815,000 -8,927,000 107,854,000 96,942,000 -9,008,000 -103,381,000 14,882,000 -84,352,000 -37,367,000 23,330,000 379,729,000 -10,854,000 173,081,000 20,690,000 -51,376,000 60,898,000 641,000 -35,503,000 -55,584,000      
          effect of exchange rate on cash and cash equivalents and restricted cash
        		-225,000 -201,000 -83,000 23,000 -136,000 -31,000 -24,000 -38,000 -18,000 -110,000 -1,000 50,000 -45,000 -237,000 -271,000 -104,000 1,000 1,000 -55,000 1,000    41,000  
          net increase in cash and cash equivalents and restricted cash
        		   99,349,000 50,645,000   10,021,000 -1,041,000        73,187,000 43,345,000 -65,376,000 -57,795,000      
          cash and cash equivalents and restricted cash as of beginning-of-period
        		0 0 0 178,496,000 0 0 0 223,457,000 0 0 0 215,158,000 0 0 0 354,942,000 0 0 17,000 361,564,000      
          cash and cash equivalents and restricted cash as of end-of-period
        		37,692,000 -34,966,000 -99,875,000 277,845,000 50,645,000 -10,098,000 -95,529,000 233,478,000 -1,041,000 16,899,000 15,629,000 191,970,000 20,340,000 -85,615,000 17,647,000 262,786,000 73,187,000 43,345,000 -65,359,000 303,769,000      
          gain on extinguishment of short-term debt
        		                         
          deferred tax expense
        		 627,000 -865,000 295,000                      
          repayment of long-term debt
        		 -166,755,000 0 -62,500,000     -416,701,000 -10,000,000 0 -37,500,000              
          net decrease in cash and cash equivalents and restricted cash
        		 -34,966,000         15,629,000 -23,188,000 20,340,000 -85,615,000 17,647,000 -92,156,000          
          net loss before preferred dividends and accretion of series a preferred stock
        		  -19,897,000 -64,618,000 -22,802,000 -23,137,000 1,596,000 -17,280,000                  
          extinguishment of series a preferred stock
        		                         
          loss on discontinued operations
        		            0 0            
          proceeds from transfer of membership and release of passport escrow
        		            8,000,000 0 0 22,969,000 0 0 0 42,996,000      
          disposal of non-strategic assets and divestiture of discontinued operations
        		        0    0    0 0 0 3,490,000      
          distributions to sponsors
        		            0 0 -13,784,000 -1,100,000 0 0        
          deferred tax provision
        		      -1,160,000 181,000   -2,291,000 -68,728,000   604,000 -132,000  -20,000 -209,000 -59,000     -1,360,000 
          other current operating cash outflows
        		      6,000 6,000 -51,000 -140,000 76,000 -56,000      1,443,000 -663,000 -66,000      
          gain from equity method investees
        		       -306,000 -28,000 -684,000 -155,000 -423,000 -629,000 -1,392,000 -1,952,000 -596,000          
          purchases of investments
        		       -3,000,000         -1,000 0 0 -2,994,000 -2,000 -9,721,000 -109,000 -1,338,000  
          net loss before dividends declared and accretion of series a preferred stock
        		        -33,411,000 -25,324,000 -34,323,000 -19,982,000              
          gain on transfer of membership
        		                -22,969,000 0 0 -22,969,000      
          maturities and sales of investments
        		                0 0 0 500,000 2,536,000   618,000 2,100,000 
          changes in working capital balances related to claims processing on behalf of partners
        		        -9,439,000 -25,197,000 25,546,000 7,576,000 -11,127,000 -48,682,000 34,731,000 -34,371,000 60,057,000 -1,294,000 -36,606,000 39,005,000 -3,832,000 -28,927,000 -6,963,000 33,678,000  
          repayment and repurchase of 2021 notes and financing fees
        		                         
          loss on disposal of assets
        		                8,690,000 0 0 -1,904,000    6,447,000  
          change in tax receivable agreement liability
        		          0 66,184,000 3,080,000             
          net loss
        		            -11,349,000 2,123,000 -4,588,000 -5,350,000 -5,647,000 -13,040,000 -9,107,000 -9,807,000      
          impairment of equity method investees
        		                         
          loan for implementation funding
        		                     0 0 -400,000  
          impact to cash and cash equivalents and restricted cash from initial consolidation
        		                         
          other investing activities
        		                         
          repayment of credit agreement including settlement of warrants
        		                         
          proceeds from issuance of long term debt, net of offering costs
        		                         
          loss on repayment of debt
        		                2,185,000 0 0 19,158,000      
          gain on discontinued operations
        		                         
          unrealized loss on investments
        		                         
          repayment and termination of credit agreement including settlement of warrants
        		                         
          change in fair value of contingent consideration and indemnification asset
        		                14,100,000 -225,000 0 -594,000 4,352,000 2,570,000 756,000 -3,818,000  
          impairment of equity method investments
        		                         
          interest from customer advance for regulatory capital requirements
        		                -81,000    -81,000 -472,000 -666,000 -650,000  
          customer advance for regulatory capital requirements
        		                         
          investments in equity method investees
        		                         
          amount received from escrow in asset acquisition
        		                         
          issuance of warrant liability
        		                         
          taxes withheld and paid for vesting of restricted stock units
        		                -453,000 -255,000 -455,000 -2,687,000   -143,000 -1,188,000  
          cash paid for asset acquisitions
        		                 -417,000 0 -1,472,000      
          repayment and termination of credit agreement including settlement of warrants.
        		                 0 0 -98,420,000      
          proceeds from issuance of 2024 notes, net of offering costs
        		                         
          repurchase of 2021 notes and financing fees
        		                         
          bad debt expense
        		                   2,407,000      
          principal repayment of implementation funding loan and regulatory and capital requirements
        		                         
          loss on disposal of assets and consolidation
        		                         
          loss on extinguishment of debt
        		                    0     
          prepaid expenses and other current and noncurrent assets
        		                    -1,773,000 13,025,000 -5,371,000 1,459,000  
          cash paid for asset acquisitions or business combinations
        		                         
          disposal of non-strategic assets
        		                    0 0 0 -2,287,000  
          investments in and advances to equity method investees
        		                         
          impact to cash and cash equivalents and restricted cash from initial consolidation of passport
        		                         
          purchase and maturities of restricted investments
        		                    0 -2,000    
          repurchase of 2021 notes and lender fees
        		                         
          cash flows used in operating activities
        		                         
          net income
        		                     -38,170,000 -203,521,000 -78,752,000 -186,278,000 
          adjustments to reconcile net income to net cash and restricted cash from operating activities:
        		                         
          gain on disposal of assets
        		                     0    
          (gain) income from equity method investees
        		                         
          equity method investments impairment
        		                     0 0 47,133,000  
          cash flows from (used in) investing activities
        		                         
          cash flows from (used in) financing activities
        		                         
          deferred financing costs related to 2025 notes
        		                         
          cash flows from (used in) operating activities
        		                         
          (income) income from equity method investees
        		                         
          cash flows used in investing activities
        		                         
          maturities of investments
        		                         
          cash flows (used in) from financing activities
        		                         
          income from equity method investees
        		                       412,000  
          net cash and restricted cash (used in) from financing activities
        		                       32,574,000  
          investments in and purchases of property and equipment
        		                         
          proceeds from issuance of common stock, net of stock issuance costs
        		                         
          change in warrant liability
        		                         
          proceeds from issuance of long-term debt, net of issuance costs
        		                         
          adjustments to reconcile net income to net cash and restricted cash
        		                         
          provided by operating activities:
        		                         
          (gain) loss on disposal of assets
        		                         
          non-cash interest income
        		                         
          other
        		                        276,000 
          accounts receivables, net and contract assets
        		                         
          reserves for claims and performance-based arrangements
        		                         
          rou operating assets
        		                         
          principal repayment of implementation funding loan and regulatory capital requirements
        		                         
          purchases of restricted investments
        		                         
          maturities of restricted investments
        		                         
          principal repayment of implementation funding loan
        		                         
          income from lease abandonment
        		                         
          acceleration of unvested equity awards for valence health employees
        		                         
          claims reserves
        		                         
          proceeds from issuance of convertible notes, net of issuance costs
        		                         
          accounts receivables
        		                        -9,956,000 
          contract assets
        		                         
          principal repayment for implementation funding loan
        		                         
          purchases of property and equipment
        		                        -7,260,000 
          purchases and maturities of restricted investments
        		                         
          change in restricted cash held on behalf of partners for claims processing
        		                         
          (income) income from affiliates
        		                         
          impact of lease termination
        		                         
          accretion of bond premium
        		                         
          investments in and advances to affiliates
        		                         
          income from affiliates
        		                         
          contract cost amortization
        		                         
          accretion of bond premium/discounts
        		                         
          amount received from vestica healthcare llc escrow
        		                         
          gain on consolidation
        		                         
          change in fair value of contingent liability
        		                         
          prepaid expenses and other assets
        		                         
          other liabilities
        		                         
          cash acquired upon consolidation of affiliate
        		                         
          cash paid for asset acquisition or business combination
        		                         
          purchase of restricted investments
        		                         
          payments of deferred offering costs
        		                         
          adjustments to reconcile net income to net cash from operating activities:
        		                         
          undistributed losses from affiliates
        		                         
          prepaid expenses and other current assets
        		                        -429,000 
          accounts payable, net of change in restricted cash and restricted investments
        		                         
          net cash from operating activities
        		                        -21,918,000 
          capital expenditures
        		                        -7,260,000 
          free cash flows
        		                        -29,178,000 
          change in restricted cash and restricted investments
        		                         
          net cash from investing activities
        		                        -18,466,000 
          net cash from financing activities
        		                        -204,000 
          net increase in cash and cash equivalents
        		                        -40,588,000 
          cash and cash equivalents as of beginning-of-period
        		                        145,726,000 
          cash and cash equivalents as of end-of-period
        		                        105,138,000 
          loss on change in fair value of contingent consideration
        		                         
          taxes withheld for vesting of restricted stock units
        		                        -318,000 
          gain on change in fair value of contingent liability
        		                         
          acceleration of unvested equity awards for valence employees
        		                         
          other current liabilities
        		                         
          proceeds from initial public offering, net of offering costs
        		                         
          supplemental disclosure of non-cash investing and financing activities
        		                         
          non-cash contribution of common stock to evolent health llc prior to the offering reorganization
        		                         
          non-cash repurchase of series a preferred stock
        		                         
          non-cash issuance of series b-1 preferred stock
        		                         
          non-cash issuance of class a common stock
        		                         
          non-cash deferred financing costs payable
        		                         
          acquisition consideration payable
        		                         
          accrued property and equipment purchases
        		                        98,000 
          effects of the offering reorganization
        		                         
          reclassification of deferred offering costs acquired to additional paid-in capital
        		                         
          conversion of existing equity as part of the offering reorganization
        		                         
          issuance of class b common stock
        		                         
          assumption of non-controlling interest as a result of merger with tpg affiliate
        		                         
          effects of the secondary offering
        		                         
          decrease in non-controlling interests as a result of the exchange
        		                         
          changes in assets and liabilities:
        		                         
          change in restricted cash
        		                        1,194,000 
          loss from affiliates
        		                        14,000 
          cash paid in connection with acquisition
        		                        -14,500,000 
          stock issued in connection with business combinations
        		                        10,534,000 
          effects of the offering reorganization:
        		                         
          depreciation and amortization
        		                         
          adjustments to reconcile net income to net cash from operating
        		                         
          activities:
        		                         
          gain on deconsolidation
        		                         
          cash transferred upon deconsolidation of affiliate
        		                         
          proceeds from issuance of series b preferred stock
        		                         
          proceeds from issuance of convertible notes
        		                         
          repurchase of series a preferred stock
        		                         
          non-cash settlement of accounts receivable through reacquisition of series a preferred stock
        		                         
          conversion of accrued interest from convertible notes to equity
        		                         
          conversion of convertible notes to equity
        		                         
          gain on offering reorganization
        		                         
          non-cash repurchase of series a preferred shares
        		                         
          unsettled investment purchases
        		                         
          non-cash issuance of series b-1 preferred shares
        		                         
          non-cash issuance of class a common shares